Endonovo Therapeutics (ENDV) Payables (2016 - 2023)
Endonovo Therapeutics has reported Payables over the past 13 years, most recently at $8.3 million for Q3 2023.
- Quarterly results put Payables at $8.3 million for Q3 2023, up 196.63% from a year ago — trailing twelve months through Sep 2023 was $8.3 million (up 196.63% YoY), and the annual figure for FY2022 was $8.0 million, up 1.68%.
- Payables for Q3 2023 was $8.3 million at Endonovo Therapeutics, up from $8.2 million in the prior quarter.
- Over the last five years, Payables for ENDV hit a ceiling of $8.3 million in Q3 2023 and a floor of $458885.0 in Q1 2019.
- Median Payables over the past 5 years was $2.7 million (2022), compared with a mean of $4.1 million.
- Biggest five-year swings in Payables: tumbled 94.39% in 2019 and later soared 884.72% in 2020.
- Endonovo Therapeutics' Payables stood at $7.5 million in 2019, then grew by 0.83% to $7.5 million in 2020, then increased by 5.03% to $7.9 million in 2021, then grew by 1.68% to $8.0 million in 2022, then increased by 2.71% to $8.3 million in 2023.
- The last three reported values for Payables were $8.3 million (Q3 2023), $8.2 million (Q2 2023), and $7.8 million (Q1 2023) per Business Quant data.